Imagion resumes MagSense nanoparticle manufacturing capabilities
Imagion Biosystems (ASX: IBX) said it will resume MagSense nanoparticle manufacturing capabilities ahead of its Phase 1b/2 clinical trial and potential commercialization, contracting nanoComposix as its CDMO.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.